Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies

10 Nov 2021

Abstract excerpt

Diffuse midline glioma (DMG) is a deadly pediatric and adolescent central nervous system (CNS) tumor localized along the midline structures of the brain atop the spinal cord. With a median overall survival (OS) of just 9-11-months, DMG is characterized by global hypomethylation of histone H3 at lysine 27 (H3K27me3), driven by recurring somatic mutations in H3 genes including, HIST1H3B/C (H3.1K27M) or H3F3A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34759345
DOI: 10.1038/s41388-021-02102-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategiesPMID 34759345Read ↗

H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions.Semantic proximity Read ↗

Pediatric diffuse midline glioma: Understanding the mechanisms and assessing the next generation of personalized therapeuticsSemantic proximity Read ↗

Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomesSemantic proximity Read ↗

Epigenetic mechanisms and therapeutic advances in diffuse midline glioma (Review).Semantic proximity Read ↗

Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adultsSemantic proximity Read ↗

New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline GliomaSemantic proximity Read ↗

Therapeutic Targets in Diffuse Midline Gliomas—An Emerging LandscapeSemantic proximity Read ↗

Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.Semantic proximity Read ↗

A road map for the treatment of pediatric diffuse midline glioma.Semantic proximity Read ↗

Pediatric Diffuse Midline Glioma H3K27-Altered: From Developmental Origins to Therapeutic ChallengesSemantic proximity Read ↗

Epigenetic programming of pediatric high-grade glioma: Pushing beyond proof of concept to clinical benefitSemantic proximity Read ↗

Transcriptomic and proteomic spatial profiling of pediatric and adult diffuse midline glioma H3 K27-Altered.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.